This post was originally published on this site
Furthermore, TALK’s shares have lost 35.3% since the company announced on November 15 that its co-founder and CEO, Oren Frank, and its co-founder and Head of Clinical Services, Roni Frank, will step down from their respective roles and from the company’s board of directors.
Consequently, three analysts have lowered their recommendations on the stock. Stephanie Davis, an analyst with SVB Leerink, said, “Our downgrade comes down to a combination of missteps in both execution and messaging.” So, TALK’s near-term prospects look bleak.
